Selectivity of Recognition of Variable (V) Regions of Autoantibodies by Intravenous Immunoglobulin (IVIg) |
| |
| Institution: | 1. Center for Translational Science, Children''s National Health System, Washington, DC;2. Division of Pediatric Nephrology, LeBonheur Children''s Hospital and St. Jude Children''s Research Hospital, Memphis, TN;3. Renal Section, Texas Children''s Hospital, Houston, TX;4. University College London Institute of Child Health and Nephrology Department, Great Ormond Street Hospital, London, United Kingdom;5. Division of Pediatric Nephrology, Children''s Hospital Colorado, Aurora, CO;6. Department of Pediatrics, Case Western Reserve University and Cleveland Clinic Children''s Hospital, Cleveland, OH;7. Department of Pediatric Nephrology, Birmingham Children''s Hospital, National Health Service Foundation Trust, Birmingham, United Kingdom;8. Department of Pediatrics and Center for Molecular Medicine, Cologne University Hospital, Cologne, Germany;9. Department of Surgery, Cincinnati Children''s Hospital Medical Center, Cincinnati, OH;10. Division of Pediatric Hepatology, Children''s Hospital of Pittsburgh, Pittsburgh, PA;11. Section of Transplantation and Immunology, Department of Surgery, Yale University School of Medicine, New Haven, CT;12. Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD;13. Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada;14. Division of Pediatric Gastroenterology and Hepatology, Seattle Children''s Hospital, Seattle, WA;15. Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Health Science Center at Houston, Houston, TX;16. Department of Pediatrics, The University of Texas Health Science Center at Houston, Houston, TX;17. Division of Neonatology, Children''s Hospital of Philadelphia, Philadelphia, PA;18. Division of Neonatology, University of California at San Francisco Children''s Hospital, San Francisco, CA;19. Division of Maternal Fetal Medicine and Reproductive Genetics, Brigham and Women''s Hospital, Boston, MA;20. Bioscientia, Center for Human Genetics, Ingelheim, Germany;21. Department of Nephrology and Center for Clinical Research, University Hospital Freiburg, Freiburg, Germany;22. Department of Pediatrics, Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD;23. Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD;24. Department of Allied Health Sciences and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC;25. Department of Neuropsychology, Children''s National Health System, Washington, DC;26. Division of Nephrology, Children''s Hospital of Philadelphia, Philadelphia, PA;27. Division of Nephrology, Tufts Medical Center, Boston, MA;28. Division of Kidney, Urologic, and Hematologic Diseases, NIDDK, National Institutes of Health, Bethesda, MD;1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;2. Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;3. Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;1. College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, 325035, China;2. Guangxi Key Laboratory of Calcium Carbonate Resources Comprehensive Utilization, Hezhou University, Hezhou, 542899, China |
| |
| Abstract: | In the present study, we demonstrate that intravenous immunoglobulin (IVIg) is capable of binding to variable (V) regions of anti-endothelial cell antibodies (AECA) of healthy donors and patients with systemic lupus erythematosus (SLE). Among V regions of AECAs, IVIg selectively recognized certain idiotypes expressed by the autoantibodies of a given individual, in the case of both natural and SLE-associated AECAs. These observations provide new and direct evidence that IVIg interacts idiotypically with V regions of autoantibodies and that the efficacy of such interaction depends on individual autoantibody specificity. Our findings may be relevant for the understanding of the mechanisms that control expression of natural autoantibody activity in serum and for that of the differences in response to IVIg therapy that are seen between patients with autoimmune disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
